Literature DB >> 27623940

Aberrant microRNA expression in tumor mycosis fungoides.

E Papadavid1,2, M Braoudaki3,4, M Bourdakou5, A Lykoudi4, V Nikolaou1, G Tounta4, A Ekonomidi1, E Athanasiadis5, G Spyrou5, C Antoniou1, S Kitsiou-Tzeli4, D Rigopoulos2, A Kolialexi6.   

Abstract

Herein, miRNA candidates relevant to mycosis fungoides were investigated to provide data on the molecular mechanisms underlying the pathogenesis of the disease. The miRNA expression profile of skin biopsies from patients with tumor stage MF (tMF) and normal donors was compared using miRNA microarrays. Overall, 154 miRNAs were found differentially expressed between tMF and the control cohort with the majority of them being up-regulated (57 %). Among the upregulated miRNAs, miR-3177, miR-514b-3p, miR-1267, and miR-1282 were exclusively detected in 70 % of tMF. Additional upregulated miRNAs included miR-34a, miR-29a, let-7a*, and miR-210, while miR-200c* was identified among the downregulated ones. Quantitative real-time polymerase chain reaction was used to further investigate the expression profiles of miR-34a and miR-29a and validated the overexpression of miR-34a. Enrichment studies revealed that the target genes of the differentially expressed miRNAs were important in several cancer-related signaling pathways. The overlapping relationship of the target genes among tMF, Sezary syndrome, and atopic dermatitis revealed several common and disease-specific genes. Collectively, our study modulated miR-34a as a candidate oncogenic molecule and miR-29a as a putative tumor suppressor highlighting their promising potential in the molecular pathogenesis of tMF.

Entities:  

Keywords:  Pathway analysis; T-cell lymphomas; miRNA microarrays; qRT-PCR

Mesh:

Substances:

Year:  2016        PMID: 27623940     DOI: 10.1007/s13277-016-5325-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  53 in total

1.  Notch1 as a potential therapeutic target in cutaneous T-cell lymphoma.

Authors:  Maria R Kamstrup; Lise Mette Rahbek Gjerdrum; Edyta Biskup; Britt Thyssing Lauenborg; Elisabeth Ralfkiaer; Anders Woetmann; Niels Ødum; Robert Gniadecki
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Correlations of serum Interleukin-16, total IgE, eosinophil cationic protein and total eosinophil counts with disease activity in children with atopic dermatitis.

Authors:  K-G Wu; T-H Li; C-J Chen; H-I Cheng; T-Y Wang
Journal:  Int J Immunopathol Pharmacol       Date:  2011 Jan-Mar       Impact factor: 3.219

3.  IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases.

Authors:  Anne Pham-Ledard; Martina Prochazkova-Carlotti; Elodie Laharanne; Béatrice Vergier; Thomas Jouary; Marie Beylot-Barry; Jean-Philippe Merlio
Journal:  J Invest Dermatol       Date:  2009-10-08       Impact factor: 8.551

4.  Association between serum IL-16 levels and the degree of sensitization in patients with atopic dermatitis.

Authors:  Georgina Nagy; Krisztián Gáspár; Beatrix Irinyi; Mónika Gál; Judit Tumpek; Edit Gyimesi; Sándor Sipka; Éva Remenyik; Péter Szodoray; Andrea Szegedi
Journal:  Int Arch Allergy Immunol       Date:  2011-03-29       Impact factor: 2.749

Review 5.  MicroRNA control of signal transduction.

Authors:  Masafumi Inui; Graziano Martello; Stefano Piccolo
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03-10       Impact factor: 94.444

Review 6.  The microRNA networks of TGFβ signaling in cancer.

Authors:  V P Sivadas; S Kannan
Journal:  Tumour Biol       Date:  2013-12-10

7.  The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients.

Authors:  J Boysen; S Sinha; T Price-Troska; S L Warner; D J Bearss; D Viswanatha; T D Shanafelt; N E Kay; A K Ghosh
Journal:  Leukemia       Date:  2013-10-18       Impact factor: 11.528

8.  Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.

Authors:  Xi Wang; Jinge Li; Ke Dong; Fang Lin; Min Long; Yongri Ouyang; Junxia Wei; Xi Chen; Yuanyuan Weng; Ting He; Huizhong Zhang
Journal:  Cell Signal       Date:  2014-12-10       Impact factor: 4.315

9.  WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013.

Authors:  Jing Wang; Dexter Duncan; Zhiao Shi; Bing Zhang
Journal:  Nucleic Acids Res       Date:  2013-05-23       Impact factor: 16.971

Review 10.  RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action.

Authors:  Julien Masliah-Planchon; Simon Garinet; Eric Pasmant
Journal:  Oncotarget       Date:  2016-06-21
View more
  4 in total

1.  MicroRNAs and their signaling pathway in mycosis fungoides.

Authors:  Zhiyuan Sun; Xiaona Yao; Xing Ding; Xun Li; Xuewen Tian
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

2.  Clinical utility of microRNA-451 as diagnostic biomarker for human cancers.

Authors:  Zhanzhan Li; Yanyan Li; Jun Fu; Na Li; Liangfang Shen
Journal:  Biosci Rep       Date:  2019-01-15       Impact factor: 3.840

Review 3.  The Role of microRNA in Pathogenesis, Diagnosis, Different Variants, Treatment and Prognosis of Mycosis Fungoides.

Authors:  Pengfei Wen; Yao Xie; Lin Wang
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

Review 4.  MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.

Authors:  Maria Gluud; Andreas Willerslev-Olsen; Lise Mette Rahbek Gjerdrum; Lise M Lindahl; Terkild B Buus; Mads Hald Andersen; Charlotte Menne Bonefeld; Thorbjorn Krejsgaard; Ivan V Litvinov; Lars Iversen; Jürgen C Becker; Jenny L Persson; Sergei B Koralov; Thomas Litman; Carsten Geisler; Anders Woetmann; Niels Odum
Journal:  Cancers (Basel)       Date:  2020-05-13       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.